FAQS | EQ-5D-5L
Evidence on the implications for cost-effectiveness ratios when switching from EQ-5D-3L to EQ-5D-5L is limited. Some work has been done on this, using mapping instead of a direct comparison of the EQ-5D-3L and EQ-5D-5L (see Wailoo et al, 2021), showing that there are differences, but that these differences are not unidirectional between countries. Furthermore, simulation…
Read MoreResponses to the EQ-5D-5L and EQ-5D-3L may differ as their descriptive systems are different. For example, the most extreme response option on the mobility dimension is “confined to bed” in the EQ-5D-3L and “unable to walk about” in the EQ-5D-5L, which may lead to different responses from respondents. The expanded level structure and the different…
Read MoreThere is growing evidence on the comparative psychometric performance of the EQ-5D-3L and EQ-5D-5L descriptive systems. A published systematic review by Buchholz and colleagues found that the 5-level version performed better, or at least the same in terms of measurement properties when compared to the 3-level version. This review supports the use of both the…
Read MoreYes, please browse to the relevant section of our website. See: example demos
Read MorePlease note that in the UK, as an interim measure whilst a new UK EQ-5D-5L value set is being developed, a different mapping function is recommended for use in submissions to NICE (see EQ-5D-5L valuation webpage) for more information.
Read MoreA standardized valuation study protocol (called EQ-VT) was developed by the EuroQol Group to create standard value sets for the EQ-5D-5L. This protocol is based on the use of the composite time trade-off (cTTO) valuation technique, supplemented by a discrete choice experiment (DCE). We recommend EQ-5D-5L users to use the standard value sets, as these…
Read MoreEQ-5D is used by scientists across the world in different settings and for many different diseases. It is used by academia (e.g. universities, research institutes), governments (national, regional, municipal), industry (e.g. pharmaceuticals, medical devices) and by hospitals and clinics (e.g. hospitals, GP practices). At an international level, the pharmaceutical industry and scientific groups are the…
Read MoreNo, without the prior written consent of the EuroQol Office, you are not permitted to use, reproduce, alter, amend, convert, translate, publish or make available in whatever way (digital, hard-copy etc.) the EQ-5D and related proprietary materials. Please contact the EuroQol Office if you would like to reproduce EQ-5D.
Read MoreYes. Please note that without the prior written consent of the EuroQol Office, you are not permitted to use, reproduce, alter, amend, convert, translate, publish or make available in whatever way (digital, hard-copy etc.) the EQ-5D and related proprietary materials. The EuroQol Research Foundation stresses that any and all copyrights in the EQ-5D, its (digital)…
Read MoreEuroQol does not charge a license fee for non-commercial uses of EQ-5D. After registering to use the instrument, EQ-5D can be used free of charge for academic, educational, public health, and other non-commercial purposes. A small fee may be charged for screen shot review if data is collected digitally on a platform other than REDCAP®,…
Read More